In-vitro activity of cefoxitin against recent clinical bacterial isolates.
The susceptibility of 635 clinical isolates of bacteria to cefoxitin was determined. Isolates from the urinary tract showed 97% sensitivity, isolates from infected wounds showed 93% sensitivity and 82% of blood culture isolates were sensitive. Streptococcus faecalis isolates showed only 50% sensitivity and pseudomonas organisms were predominantly resistant. Bacteria isolated from unprepared heart valves submitted for use as homografts showed only 71% sensitivity due to the large proportion of Streptococcus and Pseudomonas species isolated.
D001419:Bacteria / Q000187:drug effects*; D001769:Blood / Q000382:microbiology; D002440:Cefoxitin / Q000494:pharmacology*; D002511:Cephalosporins / Q000494:pharmacology*; D004352:Drug Resistance, Microbial; D006351:Heart Valves / Q000382:microbiology; D006801:Humans; D008826:Microbial Sensitivity Tests; D011549:Pseudomonas / Q000187:drug effects; D013291:Streptococcus / Q000187:drug effects; D014946:Wound Infection / Q000382:microbiology
D002511:Cephalosporins; D002440:Cefoxitin